🇺🇸 FDA
Patent

US 8466290

STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient

granted A61KA61K31/4709A61P

Quick answer

US patent 8466290 (STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient) held by Pharmadesign, Inc. expires Mon Jun 13 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Pharmadesign, Inc.
Grant date
Tue Jun 18 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/4709, A61P, A61P19/02, A61P29/00